$GILD,...Gilead to fight ruling from India patent office
Gilead Sciences (NASDAQ:GILD) will appeal the ruling by the India patent office that denied its application for Sovaldi (sofosbuvir). The company says that it will strongly defend its intellectual property and is exploring additional procedural options
News 
Market Data 
Discover 
AI
